{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:27:08Z","timestamp":1789547228921,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jchf.2023.06.024","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T14:06:29Z","timestamp":1692194789000},"page":"1316-1319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Precision Medicine in Cardiogenic Shock"],"prefix":"10.1016","volume":"11","author":[{"given":"Alexandre","family":"Mebazaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabri","family":"Soussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2023.06.024_bib1","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S2213-2600(21)00172-7","article-title":"Optimising clinical trials in acute myocardial infarction complicated by cardiogenic shock: a statement from the 2020 Critical Care Clinical Trialists Workshop","volume":"9","author":"Arrigo","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jchf.2023.06.024_bib2","first-page":"100120","article-title":"Advances in the staging and phenotyping of cardiogenic shock","volume":"1","author":"Jentzer","year":"2022","journal-title":"JACC: Adv"},{"key":"10.1016\/j.jchf.2023.06.024_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/ALN.0000000000003600","article-title":"Evaluation of biomarkers in critical care and perioperative medicine: a clinician\u2019s overview of traditional statistical methods and machine learning algorithms","volume":"134","author":"Soussi","year":"2021","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jchf.2023.06.024_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-2600(14)70097-9","article-title":"Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials","volume":"2","author":"Calfee","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jchf.2023.06.024_bib5","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2019.5791","article-title":"Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis","volume":"321","author":"Seymour","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jchf.2023.06.024_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13054-022-03972-8","article-title":"Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: a secondary latent class analysis of the FROG-ICU cohort","volume":"26","author":"Soussi","year":"2022","journal-title":"Crit Care"},{"key":"10.1016\/j.jchf.2023.06.024_bib7","article-title":"Phenotyping cardiogenic shock","volume":"10","author":"Zweck","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jchf.2023.06.024_bib8","first-page":"1006","article-title":"Validation of cardiogenic shock phenotypes in a mixed cardiac intensive care unit population","volume":"99","author":"Jentzer","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.jchf.2023.06.024_bib9","first-page":"1304","article-title":"Clinical course of patients in cardiogenic shock stratified by phenotype","volume":"11","author":"Zweck","year":"2023","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jchf.2023.06.024_bib10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-2600(18)30177-2","article-title":"Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial","volume":"6","author":"Calfee","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jchf.2023.06.024_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/hrt.2010.195511","article-title":"Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events","volume":"97","author":"Jolly","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jchf.2023.06.024_bib12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1136\/thoraxjnl-2017-211090","article-title":"Stability of ARDS subphenotypes over time in 2 randomised controlled trials","volume":"73","author":"Delucchi","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jchf.2023.06.024_bib13","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/sim.9437","article-title":"Propensity score methods for observational studies with clustered data: a review","volume":"41","author":"Chang","year":"2022","journal-title":"Stat Med"},{"key":"10.1016\/j.jchf.2023.06.024_bib14","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00134-021-06537-5","article-title":"Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial","volume":"47","author":"Laterre","year":"2021","journal-title":"Intensive Care Med"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923003773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177923003773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:04:45Z","timestamp":1761973485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177923003773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":14,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2213177923003773"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2023.06.024","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Medicine in Cardiogenic Shock","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2023.05.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}